

DAFTAR PUSTAKA

Aarons, L. (1991). Population Pharmacokinetics: Theory And Practice, *Br. J. clin. Pharmac.* 32: 669-670.

Abdessadek, M., Tadmori, A.E., El-Attari, A., Diarra, M., Magoul, R., Ajdi, F., El-Ouezzani, S., and Khabbal, Y. (2015). Simple HPLC-UV method for determination of metformin in human plasma and erythrocytes application to therapeutic drug monitoring, *Int. J. Pharm. Pharm. Sci.*, 7 (11): 35–39.

Agrawal, N., Agrawal, M.K., Kumari, T., Kumar, S. (2017). Correlation between Body Mass Index and Blood Glucose Levels in Jharkhand Population, *International Journal of Contemporary Medical Research*. 4(8):1633.

Altall, R.M., Qusti, S.Y., Filimbon, N., Alhozali, N.A., Dallol, A. (2019). SLC22A1 And ATM Genes Polymorphisms Are Associated With The Risk Of Type 2 Diabetes Mellitus In Western Saudi Arabia : A Case-Control Study. *The Application of Clinical Genetics*.12: 213–219.

American Diabetes association. (2019). *Type 2 Diabetes - Symptoms, Causes, Treatment*. Available at: <https://www.diabetes.org/diabetes/type-2> (Accessed: 1 February 2020).

Amini, H., Ahmadiani, A., and Gazerani, P. (2005). Determination of Metformin In Human Plasma By High-Performance Liquid Chromatography, *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, 824(1–2):319–322.

Aroda, V. R., Knowler, W.C., Crand, J.P. (2017). Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. *Diabetologia*, 60(9):1601–1611.

Asche, C., Lafleur, J., and Conner, C. (2011). A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes', *Clin Ther.* 33(1):74-109.

Autmizguine, J., Benjamin Jr., D.K., Smith, P.B., Sampson, M., Ovetchkine, P., Cohen- Wolkowicz, M., Watt, K.M. (2014). Pharmacokinetic Studies in Infants Using Minimal-risk Study Designs. *Curr Clin Pharmacol.* 9(4): 350–358.

Ayral, G., Si Abdallah, J. F., Magnard, C., Chauvin, J., (2021). A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approach. *CPT: Pharmacometrics and Systems Pharmacology*. 10(4):318–329.

Becker, M. L., Visser, L. E., Van Schaik, R., (2009). Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. *The Pharmacogenomics Journal*. 9: 242–247.

Badan Pengawas Obat dan Makanan Republik Indonesia (2012). Farmakope

Indonesia Edisi V.

Center for Drug Evaluation and Research (CDER). (1994). *Reviewer Guidance: Validation of Chromatographic Methods*, Rockville, Maryland, USA.

Chae, J.W., Baek, I. H., Lee, B.Y., Cho, S.K., Kwon, K., (2012). Population PK/PD analysis of metformin using the signal transduction model. *British Journal of Clinical Pharmacology*, 74(5):815–823.

Chan, P.L.S., Jacqmin, P., Lavielle, M., McFadyen, L., Weatherley, B. (2011). The use of the SAEM algorithm in monolix software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. *Journal of Pharmacokinetics and Pharmacodynamics*, 38(1):41–61.

Chen, L., Takizawa, M., Chen, E., Schlessinger, A., Segenthelar, J., Ha Choi, Ji. (2010). Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered. *The Journal Of Pharmacology And Experimental Therapeutics*, 335(1):42–50

Chen S., Zhu Y., Jin, S., Zhao, D., Guo, J., Chen, L., Huang, Y. (2023). Association of glycemic control with hypertension in patients with diabetes: a population-based longitudinal study. *BMC Cardiovasc Disord.* 10;23(1):501.

Chhetri, H. P., Thapa, P., and Van Schepdael, A. (2014). Simple HPLC-UV method for the quantification of metformin in human plasma with one step protein precipitation', *Saudi Pharmaceutical Journal*. King Saud University. 22(5):483–487.

Choi, S., Jeon, S., and Han, S. (2018). Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults. *Translational and Clinical Pharmacology*. 26(1): 25–31.

Christensen, M.M., Brasch-Andersen, C., Green, H., Nielsen, F., Damkier, P., Beck-Nielsen, H., *et al.* (2011) 'The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. *Pharmacogenetics and Genomics*. 21(12): 837–850.

Chung, H., Oh, J., Yoon, S.H., Yu, K.S., Cho, J.Y., Chung, J.Y. (2018). A Non-Linear Pharmacokinetic-Pharmacodynamic Relationship Of Metformin In Healthy Volunteers: An Open-Label, Parallel Group, Randomized Clinical Study. *PLoS ONE* .13(1): e0191258.

Committee for Medicinal Products for Human Use, 2022, *ICH Guideline M10 on Bioanalytical Method Validation*, European Medicines Agency, Amsterdam, Netherlands.

Cook, M. N., Girman, C.J., Stein., P.P. (2007). Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. *Diabetic Medicine*:

24(4): 350–358.

Duffull, S.B., , Wright, D.F.B., Winter, H.R. (2010). Interpreting population pharmacodynamic analyses – a clinical viewpoint. *British Journal of Clinical Pharmacology*. 71(6):807-814.

Dujic, T., Zhou, K., Donnelly, L.A., Tavendale, R. (2015). Association of Organic Cation Transporter 1 with Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study Europe PMC Funders Group. *Diabetes*. 64(5):1786–1793.

Duong, J.K., Greenfield, J. R., Williams, K. M., and Day, R. O. (2013). Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function. *Clin Pharmacokinet*. 52(5):373-84.

Florez, J. C. (2017). The pharmacogenetics of metformin. *Diabetologia*. (2017) 60:1648–1655

Forouzanfar, M., Alexander, L., Anderson, H.R. (2015). Global, Regional, And National Comparative Risk Assessment Of 79 Behavioural, Environmental And Occupational, And Metabolic Risks Or Clusters Of Risks In 188 Countries, 1990–2013: A Systematic Analysis For The Global Burden Of Disease Study 2013. *The Lancet*. 386(10010),

Fullerton, Morgan D., Galic, S., Marcinko, K., Sikkema, S., Pulnilkunnil, T., Chen, Z.P. (2013). Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. *Nature Medicine*. 19(12):1649–1654.

Gabr, R. Q., Padwal, R. S., and Brocks, D. R. (2010). Determination Of Metformin In Human Plasma And Urine By High-Performance Liquid Chromatography Using Small Sample Volume And Conventional Octadecyl Silane Column. *Journal of Pharmacy and Pharmaceutical Sciences*. 13(4):486–494.

Gedawy, A., Al-Salami, H., and Dass, C. R. (2019). Development And Validation Of A New Analytical HPLC Method For Simultaneous Determination Of The Antidiabetic Drugs, Metformin And Gliclazide. *Journal of Food and Drug Analysis. Elsevier Ltd*. 27(1):315–322.

Gong, L., Goswami, S., Giacomini, Kathleen, M., Altman, R.B., Klein, T.E. (2012). Metformin Pathways: Pharmacokinetics And Pharmacodynamics. *Pharmacogenet Genomics*. 22(11): 820–827.

Graham, G.G., Punt, J., Arora, M., Day, R.O., Doogue, M.P., Duong, J.K., Furlong, T.J., Greenfield, J.R., Greenup, L.C., Kirkpatrick, C.M., Ray, J.E., Timmins, P.W. K. (2011). Clinical pharmacokinetics of metformin. *Clin Pharmacokinet*. 50(2): 81–98.

Grasela Jr, T. and L. S. (1991). Pharmacostatistical Modeling for Observational Data. *J Pharmacokinet Biopharm*. 19(3): 25–36.

Hakim, L., 2014, Farmakokinetika Klinik, Bursa Ilmu, p382

Hakooz, N., Jarrar, Y.B., Zihlif, M., Imraish, A., Hamed, S., Arafat, T. (2017). Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians. *Drug Metabolism and Personalized Therapy*, 32(3):157–162.

Han, T.K., Everett, R.S., Proctor, W.R. (2013). Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. *Mol Pharmacol*. 84:182–189.

Hawley, S. A., Fiona, A.R., Chevtzoff, C., (2010). Use of cells expressing γ subunit variants to identify diverse mechanisms of AMPK activation. *Cell Metabolism*. Elsevier Ltd. 11(6) : 554–565.

Hebert, M. F. (2012). *Impact of Pregnancy on Maternal Pharmacokinetics of Medications*. Clinical Pharmacology During Pregnancy, pp. 17–39.

Heckman-Stoddard, B M., DeCensi, A., Sahasrabuddhe, V.V., Ford, L. G. (2017). Repurposing metformin for the prevention of cancer and cancer recurrence,” *Diabetologia*. Diabetologia. 60(9):1639–1647

Hong, Y., and Rohatagi, S. (2008). Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus. *J Clin Pharmacol*. 48(6):696–707.

Huang, X.H., Wang, K., Huang, J.H., Xu, L., Li, L. J., Sheng, Y., Zheng, Q.S., (2014). Random sparse sampling strategy using stochastic simulation and estimation for a population pharmacokinetic study. *Saudi Pharmaceutical Journal*. 22(1):63–69.

Hyrsova, L., Smutny, T., Trejtnar, F., Pavsek, P. (2016). Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation, *Drug Metabolism Reviews*. 48(2):139–58

International Council for Harmonisation, (2022), *ICH Guideline Q2(R2) on Validation of Analytical Procedures*, European Medicines Agency, Amsterdam, Netherlands

International Diabetes Federation (2021) *IDF Diabetes Atlas 10 th edition*. 9th ed, International Diabetes Federation. 10th ed.

Jang, K., Chung, H., Yoon, J.S., Moon, S.J., Yoon, S.H., Yu, K.S., Kim, K., Chung, J.Y. Pharmacokinetics, Safety, and Tolerability of Metformin in Healthy Elderly Subjects. *J Clin Pharmacol*. 56(9):1104–10.

Johanns, M., Lai, Y.C., Hsu, M.F., Jacobs, R. (2016). AMPK antagonizes hepatic

glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B. *Nat Commun.* 8;7:10856.

Kajbaf, F., De Broe, M. E., and Lalau, J. D. (2016). Therapeutic Concentrations of Metformin: A Systematic Review. *Clinical Pharmacokinetics*. Springer International Publishing. 55(4):439–459.

Kawoosa, F., Shah, Z.A., Masoodi, S.R., Amin, A., Rasool, R., Fazili, K.M., Dar, A.H., Lone, A., and Bashir, S. (2022). Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating the response to metformin in patients with type 2 diabetes. *BMC Endocr. Disord.* 22 (1):1–11.

Kementerian Kesehatan RI Badan Penelitian dan Pengembangan. (2018). *Hasil Utama Riset Kesehatan Dasar*. Kementerian Kesehatan Republik Indonesia. pp. 1–100.

Klen, J., Goričar, K., Janež, A., Dolžan, V., (2014). The Role Of Genetic Factors And Kidney And Liver Function In Glycemic Control In Type 2 Diabetes Patients On Long-Term Metformin And Sulphonylurea Cotreatment. *Biomed Res Int.* :934729

Koepsell, H., Lips, K. & Volk, C. (2007). Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications. *Pharm Res.* 24:1227–1251.

Kong, J.Y., Kim, J.S., Kang, M.H. (2020). Renal dysfunction is associated with decline of cognitive function in community-dwelling older adults: Korean frailty and aging cohort study. *BMC Geriatr.* 20:462.

Kumar, S.A., Maiya, A.G., Shastry, B.A., Vaishali, K., Ravishankar, N., Hazari, A., Gundmi, S., Jadhav, R., 2018. Exercise And Insulin Resistance In Type 2 Diabetes Mellitus: A Systematic Review And Meta-Analysis. *Annals of Physical and Rehabilitation Medicine.* 62: 98–103.

Kusuhara, H., Ito, S., Kumagai, Y., Jiang, M., Shiroshta, T., Moriyama, Y., Inoue, K., Yuasa, H., Sugiyama, Y. (2011). Effects Of A MATE Protein Inhibitor, Pyrimethamine, On The Renal Elimination Of Metformin At Oral Microdose And At Therapeutic Dose In Healthy Subjects. *Clinical Pharmacology and Therapeutics*. Nature Publishing Group, 89(6): 837–844.

Lameshow, Ogston, S. A. (1991). Adequacy of Sample Size in Health Studies. *Biometrics.* 47(1) : 347.

Lee, S. H., and Kwon, K. (2004). Pharmacokinetic-Pharmacodynamic Modeling for the Relationship between Glucose-Lowering Effect and Plasma Concentration of Metformin in Volunteers. *Arch Pharm Res.*, 27(7): 806–810.

Li, L., Guan, Z., Li, R., Zhao, W., Hao, G., Yan, Y., Xu, Y., Liao, L., Wang, H., Gao, L., Wu, K., Gao, Y., Li, Y. (2020). Population Pharmacokinetics And Dosing

Optimization Of Metformin In Chinese Patients With Type 2 Diabetes Mellitus. *Medicine*. 99(46) : e23212.

Lin, L.K., Sun, Y., Heng, B.H., Chew, D.E.K., Chong, P.N. (2017). Medication adherence and glycemic control among newly diagnosed diabetes patients. *BMJ Open Diabetes Res Care*. 5(1):e000429.

Maida, A., Lammont, B.J., Cao, X. (2011). Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor- α in mice. *Diabetologia*. 54(2):339–349.

Mansoor., A. and Mahabadi., N. (2022). Volume of Distribution', in *NCBI book shelf*. In: StatPearls [Internet]asure Island (FL): StatPearls Publishing; 2023 Jan-. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK545280/>.

Marshall, S., Burghaus, R., Cosson, V., Cheung, S.Y.A. (2016). Good Practices in Model-Informed Drug Discovery and Development : Practice , Application , and Documentation. pp. 93–122. doi: 10.1002/psp4.12049.

Mato, E.P.M., Guewo-Fokeng, M., Essop, M. F., Owira, P.M.O., (2018). Genetic Polymorphisms Of Organic Cation Transporter 1 (OCT1) And Responses To Metformin Therapy In Individuals With Type 2 Diabetes. *Medicine*. 97:27.

Meng, Y., Bai, H., Wang, S., Li, Z., Wang, Q., Chen, L. (2017). Efficacy of Low Carbohydrate Diet for Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Diabetes Res Clin Pract*. 131:124-131.

Miller, R.A., Chu, Q., Xie, J., Foretz, M., Viollet, B. (2013). Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. *Nature*. 494(7436): 256–260.

Morino, K., Petersen, K.F., Sono, S., Choi, C.S., Samuel, V.T. (2012). Regulation Of Mitochondrial Biogenesis By Lipoprotein Lipase In Muscle Of Insulin-Resistant Offspring Of Parents With Type 2 Diabetes. *Diabetes*. 61(4):877–887.

Nielsen, F., Christensen, M. M. H., and Brøsen, K. (2014). Quantitation Of Metformin In Human Plasma And Urine By Hydrophilic Interaction Liquid Chromatography And Application To A Pharmacokinetic Study. *Therapeutic Drug Monitoring*. 36(2) : 211–217.

Nilsson, P. M., Theobald, H., Journath, G., (2004). Gender Differences In Risk Factor Control And Treatment Profile In Diabetes : A Study In 229 Swedish Primary Health Care Centres Gender Differences In Risk Factor Control And Treatment Profile In Diabetes : A Study In 229 Swedish Primary Health Care Centres. *Scand J Prim Health Care*. 22(1):27-31.

Ningrum, V.D.A., Wibowo, A., Fuaida, I., Ikawati, Z., Sadewa, A. H., Ikhsan, M. R. (2018). Validation Of An HPLC-UV Method For The Determination Of Metformin

Hydrochloride In Spiked-Human Plasma For The Application Of Therapeutic Drug Monitoring. *Research Journal of Pharmacy and Technology*. 11(6) : 2197.

Ningrum, V. D. A., Sadewa, A. and Ikawati, Z., Yuliwulandari, R., Ikhsan, M. R., Fajriyah, R. (2022). The Influence Of Metformin Transporter Gene SLC22A1 And SLC47A1 Variants On Steady-State Pharmacokinetics And Glycemic Response. *PLoS ONE*. 17(7):1–12.

Nitin, S. (2010). Hba1c And Factors Other Than Diabetes Mellitus Affecting It. *Singapore Medical Journal*. 51(8): 616–622.

Nolan, C.J., Prentki, M. (2019). Insulin Resistance And Insulin Hypersecretion In The Metabolic Syndrome And Type 2 Diabetes: Time For A Conceptual Framework Shift. *Diab Vasc Dis Res*.16(2):118-127.

Nugroho, A.K., Hakim, A.R., Hakim, L. (2017). Population-Based Approach To Analyze Sparse Sampling Data In Biopharmaceutic And Pharmacokinetic Studies Using Nonmem And Monolix. 28(4): 205–212.

Orloff, J., Min, J.Y., Mushlin, A., Flory, J., (2021). Safety And Effectiveness Of Metformin In Patients With Reduced Renal Function: A Systematic Review. *Diabetes, Obesity and Metabolism*. 23(9):2035–2047.

Patel, K., Foretz, M., Marion, A., Campbell, D., Gourlay, R., Boudaba, N., *et al.*, (2014). The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. *Nature Communications*. 5:4535.

Patyra, E., and Kwiatek, K., (2021). Application Of Micellar Mobile Phase For Quantification Of Sulfonamides In Medicated Feeds By HPLC-DAD. *Molecules*. 26(13) : 3791.

Perkeni. (2021). *Pedoman Pengelolaan dan Pencegahan diabetes Melitus Tipe 2 Dewasa di Indonesia 2019*. PB PERKENI.

Pradana, D.A., Kristin, E., Nugrahaningsih, D.A.A., Nugroho, A.K., Pinzon, R.T., (2023). Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review. *Curr Diabetes Rev*. doi: 10.2174/1573399820666230807145202. Epub ahead of print. PMID: 37550919.

Rashid, M., Syahzad, M., Mahmood, S., (2018). Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus. *Pak J Med Sci*. 35(1):1–10.

Rena, G., Hardie, D. G., and Pearson, E. R., (2017). The Mechanisms Of Action Of Metformin. *Diabetologia*. 60(9): 577–1585.

Rena, G., Pearson, E. R. and Sakamoto, K. (2013). Molecular Mechanism Of Action Of Metformin: Old Or New Insights? *Diabetologia*. 56(9):1898-906.

Reséndiz-Abarca, C.A., Flores-Alfaro, E., Suárez-Sánchez, F., Cruz, M., Valladares-Salgado, A., Del Carmen Alarcón-Romero, L., *et al.* (2019). Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study. *J Clin Pharmacol.* 59(10):1384-1390.

Rojas, L.B.A., and Gomes, M. B. (2013). Metformin: An Old But Still The Best Treatment For Type 2 Diabetes. *Journal of Chemical Information and Modeling*, 53(9): 1689–1699.

Rongen, A., Van der Aa, M.P., Matic, M., van Schaik, R.H.N., Deneer, V.H.M., van der Vorst, M.M., Knibbe, C.A.J., (2018). Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. *Paediatr Drugs.* 20(4):365-374.

Rudakov, O. B., Rudakova, L. V., and Selemenev, V. F. (2018). Acetonitrile As Tops Solvent For Liquid Chromatography And Extraction. *Journal of Analytical Chromatography and Spectroscopy.* 1(2).

Ryan, B.J., Schleh, M.W., Ahn, C., Ludzki, A.C., Gillen, J.B., Varshney, P., *et al.* (2020). Moderate-Intensity Exercise and High-Intensity Interval Training Affect Insulin Sensitivity Similarly in Obese Adults. *J Clin Endocrinol Metab.* 1;105(8):e2941–59.

Sam, S., and Ehrmann, D. A. (2017). Metformin Therapy For The Reproductive And Metabolic Consequences Of Polycystic Ovary Syndrome. *Diabetologia.* 60(9):1656–1661.

Sanchez-Rangel, E., and Inzucchi, S. E. (2017). Metformin: Clinical Use In Type 2 Diabetes. *Diabetologia.* 60(9):1586–1593.

Schmidt, H., and Radivojevic, A. (2014). Enhancing Population Pharmacokinetic Modeling Efficiency And Quality Using An Integrated Workflow. *Journal of Pharmacokinetics and Pharmacodynamics*, 41(4) : 319–334.

Schultz, A. (2018). Comparing the Effectiveness of a Low Carbohydrate Diet and Metformin on Glycosylated Hemoglobin Reduction in Type Two Diabetes Mellitus. *Physician Assistant Scholarly Project Papers.* 23.

Schwartz, S.S., Epstein, S., Corkey, B.E., Grant, S.F.A., Gavin, J.R., Aguilar, R.B. (2016). The Time Is Right For A New Classification System For Diabetes: Rationale And Implications Of The B-Cell-Centric Classification Schema. *Diabetes Care.* 39(2):179–186.

Semiz, S., Dujic, T. and Causevic, A. (2013). Review Pharmacogenetics And Personalized Treatment Of Type 2 Diabetes. (7):154–171.

Shargel, L. and Yu, A. (2016) *Applied Biopharmaceutic and Pharmacokinetics.* Mc Graw Hill Education.

Shikata, E., Yamamoto, A. R. and Takane, A. H. (2007). Human Organic Cation Transporter (OCT1 And OCT2) Gene Polymorphisms And Therapeutic Effects Of Metformin. *J Hum Genet.* 52(2):117-122.

Shokri, F., Ghaedi, H., Fard ,S.G., Movafagh, A., Abediankenari, S., Mahrooz, A., (2016). Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients. *Int J Mol Cell Med.* 5(1):1-7.

Shu, Y., Brown, C., Castro, R.A., Shi, R.J., Lin, E.T. (2007). Effect Of Genetic Variation In The Organic Cation Transporter 1 (OCT1) on Metformin Action. *Clin Pharmacol Ther.* 83(2):273-80.

Soldin, O. P., and Mattison, D. R. (2009). Sex Differences In Pharmacokinetics And Pharmacodynamics. *Clinical Pharmacokinetics*, 48(3):143–157.

Sun, L., Kwok, E., Gopaluni, B., Vahidi, O. (2011). Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus. *The Open Biomedical Engineering Journal.* 5(1):1–7.

Takane, H., Shikata, E., Otsubo, K., Higuchi, S., Ieiri, I . (2008). Polymorphism In Human Organic Cation Transporters And Metformin Action. *Pharmacogenomics.* 9(4):415–422.

Tarasova, L., Kalnina, I., Geldnere, K. (2012). Association Of Genetic Variation In The Organic Cation Transporters OCT1, OCT2 And Multidrug And Toxin Extrusion 1 Transporter Protein Genes With The Gastrointestinal Side Effects And Lower BMI In Metformin-Treated Type 2 Diabetes Patients. *Pharmacogenetics and Genomics.* 22(9):659–666.

Traynard, P., Ayrat, G., Twarogowska, M., and Chauvin, J., (2020). Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite : A Case Study of Remifentanyl. *CPT Pharmacometrics Syst Pharmacol.* 9(4):198-210.

Tulasi Prasad, N., Ajaya, B. and Sujeet Kumar, C. (2014). Sodium Dodecyl Sulphate: A Very Useful Surfactant For Scientific Investigations. *The Journal of Knowledge and Innovation.* 2(1):111–113.

Tzvetkov, M.V., Vormfelde, S.V., Balen, D., Meineke, I., Schmidt ,T., Sehr, D., 2009. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. *Clin Pharmacol Ther.* 86:299–306.

Umamaheswaran, G., Praveen, R.G., Damodaran, S.E., Das, A.K., Adithan, C. (2015). Influence Of SLC22A1 Rs622342 Genetic Polymorphism On Metformin Response In South Indian Type 2 Diabetes Mellitus Patients. *Clinical and Experimental Medicine.* 15(4):511–517.

US Food and Drug Administration (2022). *Guidance for Industry Population Pharmacokinetics.* FDA Guidance. (February). p. 31.

US Food and Drug Administration. (2018). *Bioanalytical method validation, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM)*.

Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M. (2013). Cellular and molecular mechanisms of metformin: An Overview. *Diabetology & Metabolic Syndrome*. 5(6):1–15.

Wan, E.Y.K., Yu, E.Y.T., Mak, I.L., Youn, H.M., Chan, K.S., Chan, E.W.Y., Wong, I.C.K., Lam, C.L.K. (2023). Diabetes With Poor-Control Hba1c Is Cardiovascular Disease “Risk Equivalent” For Mortality: UK Biobank And Hong Kong Population-Based Cohort Study. *BMJ Open Diabetes Research & Care*, 11(1):1–12.

Wang, X., Tang, J., Shen, C., Wang, X., Hu, H., Xie., H. (2022). Research Progress of Population Pharmacokinetic of Metformin. *BioMed Research International*, Vol 2022.

Weykamp, C. (2013). Hba1c: A Review Of Analytical And Clinical Aspects. *Annals of Laboratory Medicine*, 33(6):393–400.

Whitley, H. P., and Lindsey, W. (2009). Sex-Based Differences In Drug Activity. *American Family Physician*, 80(11):1254–1258.

Winter, M.E., 2004, Basic and Clinical Pharmacokinetics, 4 th edition, Lippincott Williams & Wilkins

WHO. (2016). *Global Report on Diabetes*. WHO, 978, pp. 6–86. Available at: http://www.who.int/about/licensing/copyright_form/index.html (Accessed: 2 February 2020).

Yoon, H., Cho, H.Y., Yoo, H.D., Kim, S.M., Lee, Y.B. (2013). Influences Of Organic Cation Transporter Polymorphisms On The Population Pharmacokinetics Of Metformin In Healthy Subjects. *AAPS Journal*. 15(2):571–580.

Zhang, J., Wang, N., Xing, X., Yang, Z., Wang, X., Yang W., (2016). Factors That Influence The Efficacy Of Acarbose And Metformin As Initial Therapy In Chinese Patients With Newly Diagnosed Type 2 Diabetes: A Subanalysis Of The MARCH Trial. *Current Medical Research and Opinion*, 32(4):713–719.

Zhou, Y., Ye, W., Wang, Yi., Jiang, Z., Meng, X. (2015). Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. *Int J Clin Exp Pathol*. 8 (8):9533-954